Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547801 · ClinicalTrials.gov registry record · NA
Effects of Human Milk Oligosaccharide Ingestion on Weight Loss and Markers of Health
A NA study of Weight Loss, sponsored by Advanced Protein Technologies Corporation.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06547801: Completed NA study of Weight Loss, sponsored by Advanced Protein Technologies Corporation.
NCT06547801 is a NA study of Weight Loss that has completed, run by Advanced Protein Technologies Corporation. The registered enrollment target is 60 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06547801, a NA study of Weight Loss, has completed, sponsored by Advanced Protein Technologies Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, double-blind, placebo-controlled, parallel arm study of 2'-fucosyllactose (2'-FL) was conducted in healthy males and females between the ages of 18 and 65 at the time of consent. 2'-FL is one of the most prominent HMOs in human milk. Preclinical studies indicate that 2'-FL feeding is prebiotic, anti-inflammatory, anti-thrombotic, and may reduce skeletal muscle atrophy during energy restriction. The investigators hypothesize that supplementation of 2'-FL affects the preservation of muscle mass, strength, and markers of health during exercise and a hypo-energetic weight loss program. To test this hypothesis, the investigators will compare 3 g/day of 2'-FL with 3 g/day of maltodextrin placebo as a daily supplement.
Primary Outcome
Change in body weight (kilograms) using a calibrated digital scale
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Maltodextrin
- DIETARY_SUPPLEMENT 2'-Fucosyllactose
Study Locations (1)
Texas
- Exercise & Sport Nutrition Lab, Department of Kinesiology and Sport Management, Texas A&M University, College Station - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2024-02-22 |
| Phase | NA |
What the finished NCT06547801 record still lists
NCT06547801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 2 interventions - of which Maltodextrin is the first listed.
NCT06547801 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06547801 about?
NCT06547801 is a clinical study titled "Effects of Human Milk Oligosaccharide Ingestion on Weight Loss and Markers of Health". A randomized, double-blind, placebo-controlled, parallel arm study of 2'-fucosyllactose (2'-FL) was conducted in healthy males and females between the ages of 18 and 65 at the time of consent. 2'-FL is one of the most prominent HMOs in human milk. Preclinical studies indicate that 2'-FL feeding is p...
What is the current status of trial NCT06547801?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2023-05-04. Estimated completion is 2024-02-22.
What conditions does trial NCT06547801 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT06547801?
The interventions under investigation include: Maltodextrin (DIETARY_SUPPLEMENT), 2'-Fucosyllactose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06547801?
This trial is sponsored by Advanced Protein Technologies Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06547801 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06547801's enrollment target sits among peer trials
60 67th of 116 higher than 42 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
Circadian Time Restricted Eating
RECRUITING · NA
-
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI